|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
55.18 USD |
+1.38% | -11.80% | +63.45% | |
Published on 05/31/2025 at 08:31
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Tempus Introduces Fuses, A Program Designed To Transform Therapeutic Research And Build The Largest Diagnostic Platform Using Its Novel Foundation Model |
08:31am |
RE |
|
Sector Update: Tech Stocks Mixed Late Afternoon |
May. 28 |
MT |
|
Spruce Point Capital Management Announces Investment Opinion |
May. 28 |
RE |
|
Tempus AI Shares Fall After Short Seller Spruce Point Raises Concerns About Management, AI Capabilities |
May. 28 |
MT |
|
Tempus AI, Inc. Announces Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment |
May. 20 |
CI |
|
Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment |
May. 20 |
MT |
|
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment |
May. 20 |
RE |
|
Enterprise Development Unit Offloads Meta Platforms, Tempus AI Shares |
May. 15 |
MT |
|
Tempus AI Enters Collaboration With Boehringer Ingelheim to Advance Boehringer’s Cancer Pipeline |
May. 14 |
MT |
|
Tempus Ai, Inc. Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance Its Cancer Pipeline |
May. 14 |
CI |
|
Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum®? TKa |
May. 13 |
CI |
|
Tempus AI, Inc., Q1 2025 Earnings Call, May 06, 2025 |
May. 06 |
|
|
Tempus AI Q1 Non-GAAP Loss Narrows; Revenue Rises; Slightly Ups Full Year Guidance |
May. 06 |
MT |
|
Earnings Flash (TEM) Tempus AI Reports Q1 Revenue $255.7M, vs. FactSet Est of $248.1M |
May. 06 |
MT |
|
Earnings Flash (TEM) Tempus AI Posts Q1 Loss $-0.24 Per Share, vs. FactSet Est of $-0.28 |
May. 06 |
MT |
|
Tempus AI, Inc. Increases Earnings Guidance for Full Year 2025 |
May. 06 |
CI |
|
Tempus AI, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 06 |
CI |
|
Tempus Ai, Inc. Announces Notetaker, Its Ai-Powered Clinical Assistant for Psychiatry |
May. 05 |
CI |
|
Tempus AI, Inc. Time Network Expands Support of Phase I Clinical Trials to Accelerate Activation and Enrollment |
May. 01 |
CI |
|
Tempus AI, Inc. Introduces Loop, an AI-Powered Target Discovery and Validation Platform |
Apr. 28 |
CI |
|
Sector Update: Health Care Stocks Edge Up Late Afternoon |
Apr. 23 |
MT |
|
Tempus AI to Build Oncology Multimodal Foundation Model in Partnership With AstraZeneca, Pathos AI |
Apr. 23 |
MT |
|
Tempus AI Inc Announces Strategic Collaborations With AstraZeneca And Pathos |
Apr. 23 |
RE |
|
Tempus Signs Expanded Strategic Agreements with Astrazeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology |
Apr. 23 |
CI |
|
BTIG Initiates Tempus AI at Buy With $60 Price Target |
Apr. 21 |
MT |
TEM: Dynamic Chart
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company’s AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
More about the company
Buy
Average target price
65.50USD
Spread / Average Target
+18.70%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
